Open AccessNovel therapies for the management of type 2 diabetes mellitus: Part 1. Pramlintide and bromocriptine‐ QR (2型糖尿病治疗新药：第1部分.普兰林肽与溴隐亭‐QR)
Author(s) -
Grunberger George
Publication year - 2013
Publication title -
journal of diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.949
H-Index - 43
eISSN - 1753-0407
pISSN - 1753-0393
DOI - 10.1111/1753-0407.12034
Subject(s) - medicine , amylin , diabetes mellitus , bromocriptine , dopaminergic , hypoglycemia , type 2 diabetes mellitus , agonist , type 2 diabetes , endocrinology , pharmacology , receptor , dopamine , islet , hormone , prolactin
Several classes of antidiabetic agents have been introduced into the market place over the past dozen years. As our understanding of the underlying pathophysiology of type 2 diabetes has advanced, attempts have been made to address these defects specifically. This brief review focuses on our experience with two such pharmacological approaches: (i) a synthetic amylin analog addressing amylin deficiency; and (ii) a dopaminergic agonist, focused on enhancing the lowered dopaminergic tone in patients with type 2 diabetes. Importantly, the use of these agents is not associated with hypoglycemia or weight gain.